News
SRRK
13.85
-0.72%
-0.10
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?
Scholar Rock Holding Corporation (NASDAQ:SRRK) does have debt on its balance sheet. But the company has more cash than debt, and is unlikely to be in trouble with its lenders. Debt is an important factor in assessing how risky a company is. Scholar Rock Holding had a negative free cash flow of US$145m over the last year. The company also has US$50.0m in debt, but also has a large amount of cash on hand.
Simply Wall St · 4d ago
Weekly Report: what happened at SRRK last week (0408-0412)?
Weekly Report · 4d ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Scholar Rock is a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy and other serious diseases. The company granted inducement equity awards to two newly hired employees. Scholar Rock is the only company to show clinical proof-of-concept for a muscle-targeted treatment in SMA.
Barchart · 04/12 15:15
Weekly Report: what happened at SRRK last week (0401-0405)?
Weekly Report · 04/08 09:30
Scholar Rock Holding Price Target Maintained With a $20.00/Share by Truist Securities
Dow Jones · 04/03 13:52
Truist Securities Reiterates Buy on Scholar Rock Holding, Maintains $20 Price Target
Benzinga · 04/03 13:42
Weekly Report: what happened at SRRK last week (0325-0329)?
Weekly Report · 04/01 09:30
Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK) The analyst commences coverage of Scholar Rock with a Strong Buy rating and a price target of $30. The company's lead program, apitegromab, is in a Phase 3 trial for Spinal Muscular Atrophy. Scholar Rock is exploring opportunities in the obesity market with SRK-439.
Benzinga · 03/28 18:42
S&P 500 Posts a Record High on Optimism the Fed Can Achieve a Soft Landing
S&P 500 posts a new all-time high after Q4 GDP report revised higher. Energy stocks support the overall market as crude prices rise to a 1-week high. European stocks rally to a new 23-year high Thursday. Hawkish comments by Fed Governor Waller pushed bond yields higher.
Barchart · 03/28 15:35
Scholar Rock Holding Price Target Announced at $30.00/Share by Raymond James
Dow Jones · 03/28 11:26
Scholar Rock Holding Initiated at Strong Buy by Raymond James
Dow Jones · 03/28 11:26
Raymond James Initiates Coverage On Scholar Rock Holding with Strong Buy Rating, Announces Price Target of $30
Benzinga · 03/28 11:16
Stocks Pressured by Hawkish Statement by a Fed Official
US stocks wavering today after strong-than-expected Q4 GDP report. Euro Stoxx 50 rises to a new 23-year high. Bond yields are higher after strong economic reports. Hawkish comments from Fed Governor Waller pushed bond yields higher. The S&P 500 and Dow Jones industrials are mixed.
Barchart · 03/28 10:32
Stocks See Support from Improved Soft-Landing Prospects
US stock indexes are slightly higher this morning. Euro Stoxx 50 rose to a 23-year high. Q4 GDP report revised higher and weekly jobless claims unexpectedly declined. Fed Governor Waller said there's no rush for the Fed to ease monetary policy. European stock markets mixed.
Barchart · 03/28 09:24
Scholar Rock Holding Price Target Maintained With a $28.00/Share by Piper Sandler
Dow Jones · 03/26 12:37
Scholar Rock Holding Is Maintained at Overweight by Piper Sandler
Dow Jones · 03/26 12:37
Piper Sandler Maintains Overweight on Scholar Rock Holding, Maintains $28 Price Target
Benzinga · 03/26 12:27
Piper Sandler Remains a Buy on Scholar Rock Holding (SRRK)
TipRanks · 03/26 11:06
Scholar Rock Holding Price Target Maintained With a $20.00/Share by Truist Securities
Dow Jones · 03/25 16:30
Truist Securities Reiterates Buy on Scholar Rock Holding, Maintains $20 Price Target
Benzinga · 03/25 16:19
More
Webull provides a variety of real-time SRRK stock news. You can receive the latest news about Scholar Rock Holding through multiple platforms. This information may help you make smarter investment decisions.
About SRRK
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of medicines for the treatment of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. The Company’s product candidate includes apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy (SMA) and is in the treatment of other myostatin-related disorders. Its product candidate also includes SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 (TGFb1) for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies. The Company is advancing multiple antibody profiles toward product candidate selection, including antibodies that selectively inhibit the activation of latent TGFb1 in the context of fibrotic extracellular matrix and that avoid perturbing TGFb1 presented by cells of the immune system.